Skip to main content
OpenTrials
Completed

NCT Number: NCT02177851

The Optimization of Bioavailability From Iron Supplements: Study 2

Iron deficiency (ID) with or without anaemia (IDA) is a major public health problem worldwide, especially in women of reproductive age and young children. Iron supplementation is an effective strategy to prevent and treat ID and IDA. There is a lack of data on iron bioavailability from different supplementation regimens and how to optimize bioavailability in a cost-effective and patient-friendly way. The daily supplementation with 1-4 mg Fe/kg body weight for 3 months is reported to be the most effective method to rapidly increase iron stores in subjects with ID and IDA. In IDA patients, medical practitioners often prescribe supplementation regimens with 120 mg iron per day split into 2 doses with 60 mg iron, arguing that the splitting would increase iron bioavailability compared with one single high dose. However, there is no scientific evidence for this assumption; to the contrary, results from a recent study suggest that iron bioavailability from a second supplementation dose of iron after a first supplementation dose of iron is impaired due to increased hepcidin levels. To address this bioavailability issue, the present study will determine iron absorption from 120 mg iron administered for 3 consecutive days and compare it with that from 2 doses of 60 mg iron per day administered for 3 consecutive days. The investigators hypothesize that the iron bioavailability from the single daily dose will be lower than that from the 2 doses. By measuring also hepcidin, this study will provide important insights on the iron bioavailability from a single dose of iron and on the same amount iron split into two doses (b.i.d. administration).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Iron Deficiency Anemia Anemia, Hypochromic Anemia, Iron-Deficiency Hematologic Diseases Hemic and Lymphatic Diseases Iron Deficiencies Iron Deficiency Anemia Iron Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Human Nutrition Laboratory

Zurich, Canton of Zurich, 8092, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female, 18 to 45 years old,
  • Serum Ferritin levels <20 µg/L,
  • Normal body Mass Index (18.5-25 kg/m2),
  • Body weight <65 kg,
  • Signed informed consent

Exclusion criteria

  • Anaemia (Hb < 11.7 g/dL),
  • Elevated c-reactive protein or alpha1 glycoprotein concentrations >5.0 mg/L, >1.0 g/L, respectively,
  • Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement),
  • Continuous/long-term use of medication during the whole studies (except for contraceptives),
  • Consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration,
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months,
  • Earlier participation in a study using stable iron isotopes,
  • Known hypersensitivity or allergy to iron supplements,
  • Women who are pregnant or breast feeding,
  • Intention to become pregnant during the course of the studies,
  • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Inability to follow the procedures of the studies, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present studies,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Treatment and study plan

Single oral iron dose of 120 mg per day for 3 consecutive days

Dietary Supplement

Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days

Dietary Supplement

Primary outcomes

  1. Iron bio-availability (%) from oral iron supplementation (3x 120 mg)

    Time frame: 3 days

    Iron bioavailability will be assessed with stable isotopic labels. The shift in the isotopic ratio in human whole blood will be measured with Inductively coupled plasma mass spectrometry (ICP-MS).

  2. Serum hepcidin concentrations on the 1st day of iron supplementation

    Time frame: 1 day

  3. Iron bio-availability (%) from oral iron supplementation (6x 60 mg)

    Time frame: 6 days

    Iron bioavailability will be assessed with stable isotopic labels. The shift in the isotopic ratio in human whole blood will be measured with Inductively coupled plasma mass spectrometry (ICP-MS).

  4. Serum hepcidin concentrations on the 2nd day of iron supplementation

    Time frame: 2 days

  5. Serum hepcidin concentrations on the 3rd day of iron supplementation

    Time frame: 3 days

  6. Serum hepcidin concentrations on the 4th day of iron supplementation

    Time frame: 4 days

  7. Serum hepcidin concentrations on the 5th day of iron supplementation

    Time frame: 5 days

  8. Serum hepcidin concentrations on the 6th day of iron supplementation

    Time frame: 6 days

Sponsors and collaborators

Lead sponsor

Swiss Federal Institute of Technology

Other

Registry information

Official study title

The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Jun 30, 2014
Registry last updated
Jan 21, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.